Keros Therapeutics Inc [KROS] stock is trading at $12.02, up 5.53%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The KROS shares have gain 15.36% over the last week, with a monthly amount drifted -28.96%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Keros Therapeutics Inc [NASDAQ: KROS] stock has seen the most recent analyst activity on January 21, 2025, when Cantor Fitzgerald downgraded its rating to a Neutral. Previously, Wedbush downgraded its rating to Neutral on January 17, 2025, and kept the price target unchanged to $15. On December 16, 2024, Oppenheimer reiterated its Outperform rating and revised its price target to $63 on the stock. Guggenheim downgraded its rating to a Neutral. H.C. Wainwright reiterated its recommendation of a Buy and reduced its price target to $47 on December 13, 2024. William Blair downgraded its rating to Mkt Perform for this stock on December 12, 2024. In a note dated December 12, 2024, TD Cowen downgraded an Hold rating on this stock.
Keros Therapeutics Inc [KROS] stock has fluctuated between $9.77 and $73.00 over the past year. Currently, Wall Street analysts expect the stock to reach $101 within the next 12 months. Keros Therapeutics Inc [NASDAQ: KROS] shares were valued at $12.02 at the most recent close of the market. An investor can expect a potential return of 740.27% based on the average KROS price forecast.
Analyzing the KROS fundamentals
Keros Therapeutics Inc [NASDAQ:KROS] reported sales of 0.65M for the trailing twelve months, which represents a growth of 4750.00%. Gross Profit Margin for this corporation currently stands at -0.27% with Operating Profit Margin at -313.42%, Pretax Profit Margin comes in at -278.91%, and Net Profit Margin reading is -278.91%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.42 and Total Capital is -0.37. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.47 points at the first support level, and at 10.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.33, and for the 2nd resistance point, it is at 12.63.
Ratios To Look Out For
For context, Keros Therapeutics Inc’s Current Ratio is 19.03. In addition, the Quick Ratio stands at 19.03 and the Cash Ratio stands at 18.3. Considering the valuation of this stock, the price to sales ratio is 749.08, the price to book ratio is 0.89.
Transactions by insiders
Recent insider trading involved GORDON CARL L, Director, that happened on Aug 13 ’24 when 0.25 million shares were sold. Director, ORBIMED ADVISORS LLC completed a deal on Aug 13 ’24 to sell 0.25 million shares. Meanwhile, Shareholder OrbiMed Genesis Master Fund, L bought 29400.0 shares on Aug 13 ’24.
